Suppr超能文献

适形调强电子束放疗治疗局部残留或复发性头颈部肿瘤。

Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer.

机构信息

Department of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio.

Department of Biostatistics, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio.

出版信息

Head Neck. 2019 Jul;41(7):2148-2153. doi: 10.1002/hed.25673. Epub 2019 Feb 19.

Abstract

BACKGROUND

To report our institutional experience with intraoperative radiotherapy for persistent or recurrent head and neck cancer.

METHODS

Sixty-one patients were treated with salvage surgery and intraoperative radiation therapy (IORT). Fifty-eight patients (95%) had previously received external beam radiotherapy (EBRT) as a component of their definitive therapy. Forty-four patients (72%) had squamous cell carcinoma (SCC). Surgical margins were positive in 28 patients (46%). IORT was prescribed to a median dose of 12.5 Gy (range, 10-17.5). Twenty-three patients (38%) received a course of postoperative EBRT (median 45 Gy). Clinical outcomes were retrospectively reviewed and univariate analysis was performed using log-rank tests to correlate clinical outcomes with histology, surgical margin, and adjuvant therapy.

RESULTS

Median follow-up among surviving patients was 15.9 months. Median progression-free survival (PFS) and overall survival (OS) were 9.8 and 19.1 months, respectively. One- and 2-year rates of locoregional control (LRC) were 59% and 35%, respectively. One- and 2-year rates of PFS were 39% and 19%, respectively. One- and 2-year rates of OS were 62% and 42%, respectively. Overall survival was better for non-SCC histology (P = .03). For SCC patients, negative surgical margin showed a trend toward improved PFS (P = .09) and OS (P = .06). There was one grade-5 toxicity due to carotid rupture.

CONCLUSIONS

IORT has shown effective LRC and OS with an acceptably low rate of severe toxicity at our institution. OS was significantly better for non-SCC histology. For SCC patients, there is a trend toward improved PFS and OS associated with negative surgical margins.

摘要

背景

报告我们机构在头颈部癌症持续性或复发性疾病中应用术中放疗的经验。

方法

61 例患者接受挽救性手术和术中放疗(IORT)治疗。58 例(95%)患者在确定性治疗中曾接受过外照射放疗(EBRT)。44 例(72%)患者为鳞状细胞癌(SCC)。28 例(46%)患者手术切缘阳性。IORT 处方剂量中位数为 12.5Gy(范围 10-17.5Gy)。23 例(38%)患者接受术后 EBRT(中位数 45Gy)。回顾性分析临床结果,并采用对数秩检验对组织学、手术切缘和辅助治疗与临床结果的相关性进行单因素分析。

结果

存活患者的中位随访时间为 15.9 个月。中位无进展生存期(PFS)和总生存期(OS)分别为 9.8 个月和 19.1 个月。局部区域控制(LRC)的 1 年和 2 年率分别为 59%和 35%。PFS 的 1 年和 2 年率分别为 39%和 19%。OS 的 1 年和 2 年率分别为 62%和 42%。非 SCC 组织学的总生存期更好(P=0.03)。对于 SCC 患者,阴性手术切缘显示出改善 PFS(P=0.09)和 OS(P=0.06)的趋势。有 1 例因颈动脉破裂导致 5 级毒性。

结论

在本机构,IORT 显示出有效的局部区域控制和生存效果,且严重毒性的发生率可接受。非 SCC 组织学的 OS 明显更好。对于 SCC 患者,阴性手术切缘与 PFS 和 OS 的改善趋势相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验